INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Article

Bioengineered Lycopene Micro-Scaffolds for Diabetic Wound Regeneration

Khan Mohd Aftab Nisar*, Sejal Sunil D'silva

St. John Institute of Pharmacy and Research, Palghar

ARTICLE INFO

Published: 08 May 2026
Keywords:
Patient-centered formulation, Artificial intelligence, Personalized medicine, Drug delivery Machine learning Formulation optimization.
DOI:
10.5281/zenodo.20086013

ABSTRACT

Pharmaceutical formulation design significantly affects drug performance, safety, and therapeutic outcomes. Historically, development efforts have concentrated on ensuring product stability, bioavailability, and ease of manufacturing, often overlooking individual patient requirements. Recently, there has been a growing emphasis on patient-centered formulation strategies that prioritize treatment adherence, acceptability, and ease of administration. Factors such as age, physiological differences, genetic variability, disease conditions, swallowing capacity, sensory preferences, and lifestyle now play an essential role in dosage-form design. As personalized medicine advances, traditional uniform formulation approaches are increasingly insufficient due to variations in pharmacokinetic and pharmacodynamic responses among individuals. Artificial intelligence (AI) has emerged as a valuable tool for addressing these complexities by analyzing large and diverse datasets to support informed formulation decisions. Technologies including machine learning, deep learning, and intelligent modeling systems enable prediction and optimization of formulation components, processing parameters, and drug release behavior tailored to specific patient needs. This review explores the principles, methodologies, practical applications, advantages, limitations, and future prospects of AI-driven patient-focused formulation development, highlighting its potential to transform pharmaceutical design into a more precise and individualized discipline.

INTRODUCTION

The development of pharmaceutical formulations is an essential part of medication development and has a direct impact on the therapeutic efficacy, safety, and quality of medical products[2]. Traditionally, achieving appropriate physicochemical stability, bioavailability, and manufacturability of pharmaceutical products has been the main emphasis of formulation techniques[3]. Growing research indicates that patient acceptability, adherence, and practical

***Corresponding Author:** Khan Mohd Aftab Nisar
Address: *St. John Institute of Pharmacy and Research, Palghar*
Email : sejaldsilva220918@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

dosage form usability are just as important to therapeutic success as pharmacological efficacy, even though these factors are still crucial[4]. Healthcare systems have been moving more and more in the direction of a patient-centered approach in recent years, with a focus on better patient experiences and customized care[5]. The goal of patient-centered pharmaceutical formulation development is to create dosage forms that take into account the unique characteristics of each patient, including age, physiological state, genetic variability, disease severity, swallowing ability, taste sensitivity, and lifestyle[6]. Poor adherence, less than ideal therapeutic results, and a higher healthcare burden can result from failing to take these aspects into account[7]. The shortcomings of traditional one-size-fits-all formulation techniques have been further brought to light by the rise of personalized medicine[8]. Because patient populations differ in their pharmacokinetics and pharmacodynamics, formulation strategies must be customized to meet each patient's demands[9]. The adoption of sophisticated computational tools that can handle complicated and multidimensional datasets has been fueled by this need for customization. Because of its capacity to analyze massive data sets, spot hidden patterns, and produce predictive models, artificial intelligence [AI] has drawn a lot of interest in the pharmaceutical sciences. Robust tools for optimizing formulation composition, processing parameters, and medication delivery performance are provided by AI-based techniques like machine learning, deep learning, and expert systems. AI makes it possible to create logical, data-driven formulations that go beyond empirical trial-and-error approaches when combined with patient-centered concepts. Early prediction of crucial quality features, dissolving behavior, and in vivo performances under patient-specific physiological parameters is supported by the use of AI in formulation development. Additionally, patient-friendly dosage forms, such as age-appropriate formulations, taste-masked medicines, and modified release systems intended to improve adherence and therapeutic efficacy, are made possible by AI-driven techniques. The goal of this review is to give a thorough overview of patient-centered AI techniques used in the creation of pharmacological formulations. The overview covers the fundamental ideas, frequently used artificial intelligence methods, important applications, benefits, current difficulties, and potential future developments. demonstrating how AI has the potential to change formulation development into a paradigm that is more patient-centered and individualized[10].

The idea behind patient-centered AI:[11]

Driven systems that focus patient requirements, variability, and practical outcomes throughout the drug development lifecycle are referred to be patient-centered AI. This includes the following in formulation development:

1. Including patient-specific information (clinical, genetic, physiological)

2. Forecasting each person's reaction to formulas

3. Tailoring medicine delivery mechanisms and dose forms

4. Improvement of quality of life and patient adherence

Precision medicine and optimal therapeutic performance are supported by patient-centered AI, which moves the emphasis from population averages to individual variability.

AI methods for developing formulations:

a) Models of linear and nonlinear regression

b) Random forests and decision trees

c) SVMs, or support vector machines

d) K-NN, or K-nearest neighbors

These methods are used to forecast formulation performance metrics like stability, hardness, dissolution rate, and disintegration time.

2. Deep learning models Complex:[12]

High-dimensional datasets are handled by deep learning models, such as artificial neural networks (ANN), convolutional neural networks (CNN), and recurrent neural networks (RNN). They are especially helpful in:

a) Dosage form analysis using images

b) Identifying patterns in release and dissolution profiles

c) Multivariate formulation variable optimization

3. Ensemble and hybrid models:

Hybrid AI models improve interpretability and robustness by fusing data-driven AI techniques with mechanistic modeling. By combining several methods, ensemble learning improves prediction accuracy.

Using patient-centered AI in the creation of formulations:[13]

1. AI models for excipient selection and optimization examine patient tolerability, compatibility information, and physicochemical characteristics to suggest the best excipients. This enhances patient safety and reduces unpleasant effects.

2. Design of dosage forms Designing pills, capsules, liquids, transdermal systems, and innovative dose forms for certain populations—such as children, the elderly, and dysphagic patients—is supported by patient-centered artificial intelligence.

3. Improvement of solubility and bioavailability While taking patient variability into account, AI-driven optimization of solid dispersions, nanoparticles, lipid-based systems, and amorphous formulations increases the bioavailability of poorly soluble medications.

4. Customized medication delivery methods AI makes it possible to customize targeted, controlled release

Advantages of Artificial Intelligence Focused on Patients:[14]

1. Customized Care and Therapy Enhancement

The study of individual patient data, including genetics, age, illness severity, lifestyle, and comorbidities, is made possible by patient-centered AI. This reduces trial-and-error prescribing and improves therapeutic outcomes by enabling tailored drug selection, dosage optimization, and formulation design.

2. Enhanced Patient Safety and Decreased Side Effects

Using real-world data, AI algorithms can forecast patient-specific adverse reactions, toxicity concerns, and drug-drug interactions. This proactive risk assessment reduces avoidable adverse drug events and improves medication safety.

3. Improved Clinical Judgment

Patient-centered AI improves diagnostic precision and treatment planning by combining clinical

records, imaging, laboratory data, and patient-reported outcomes.

4. Increased Adherence and Patient Involvement

Chatbots, virtual assistants, and mobile health apps are examples of AI-powered systems that help patients learn about their disease and treatment. Patient participation in care decisions and treatment adherence is enhanced by tailored reminders and feedback.



5. Effective Formulation Design and Drug Development

By forecasting the best excipient combinations, release profiles, and dose forms based on patient requirements, patient-centered AI in pharmaceutical research supports quality by design (QbD) and Design of Experiments (DoE) methodologies.

6. Quicker and More Precise Disease Identification

Particularly in chronic and uncommon diseases, machine learning algorithms examine intricate datasets to identify early disease trends, resulting in prompt diagnosis and treatment.

7. Economical Healthcare Provision]

Patient-centered AI lowers healthcare costs while preserving high-quality care by cutting down on pointless tests, readmissions to hospitals, and ineffective therapies.

8. Predictive analytics and real-time monitoring

AI-powered wearable technology and remote monitoring systems provide ongoing patient health parameter surveillance. Early diagnosis of therapy failure or illness progression is made possible by predictive analytics.

9. Encouragement of Value-Based and Precision Healthcare

Patient-centered AI ensures that treatment choices are based on individual benefit rather than population averages, which is consistent with precision medicine and value-based care models.

10. Enhanced Quality of Life and Patient Satisfaction

AI improves patient satisfaction, trust, and general quality of life by providing individualized, effective, and responsive care, supporting a holistic approach to healthcare.

Patient-Centered Artificial Intelligence: Regulatory and Ethical Issues[15]:

1. Compliance and the Regulatory Framework

Adherence to national and international regulatory norms is necessary for the incorporation of patient-centered AI into pharmaceutical development and healthcare. Regulatory agencies prioritize performance consistency, safety, clinical relevance, and model validation. However, approval and post-deployment monitoring are complicated by the lack of standardized international criteria for AI-based solutions.

2. Confidentiality and Data Privacy

Patient-centered AI systems must strictly conform to data protection and privacy standards because they rely on sensitive personal health data. Strong anonymization, safe data storage, restricted access, and open data governance procedures are necessary for the ethical use of patient data in order to stop illegal usage and data breaches

3. Patient autonomy and informed consent

In order to ensure that patients are aware of how their data is gathered, processed, and utilized in AI-driven decision-making, ethical AI deployment requires informed consent. Patients must continue to have control over data sharing and the ability to revoke consent without sacrificing the standard of treatment.

4. Explainability and Transparency

Explainable and interpretable AI models are becoming more and more required by regulatory bodies. In order to promote confidence and facilitate collaborative decision-making while lowering the risk of blind reliance on automated systems, ethical considerations demand that clinicians and patients be able to comprehend AI-generated suggestions.

5. Equity, Fairness, and Bias

If AI systems are trained on inadequate or biased datasets, they may inadvertently perpetuate healthcare disparities. To stop discrimination against vulnerable or underrepresented groups, regulatory supervision must guarantee fairness and representativeness in AI model development.[16]

6. Liability and Accountability

When AI systems have an impact on clinical decisions, it is crucial to clearly define who is responsible. When AI-based tools cause diagnostic or therapeutic errors, developers, healthcare providers, and institutions must be held accountable under ethical and legal frameworks.

7. Post-Market Monitoring and Clinical Validation:

To guarantee long-term performance, safety, and efficacy in practical contexts, regulatory bodies need stringent clinical validation and ongoing post-deployment monitoring of AI systems. Because adaptive AI models are always changing, they pose new regulatory issues.

Obstacles and Restrictions of Patient-Centered AI in the Development of Pharmaceutical Formulations[17]:

1. Challenges Associated with Data

High-quality, patient-specific data is essential to patient-centered AI. Pharmaceutical data, however, is frequently sparse, dispersed, or inconsistent. Clinical data, patient-reported outcomes, genetic profiles, and real-world adherence data may be inadequate or inconsistent, which affects AI model accuracy and reliability.

2. Data Security and Privacy Issues

Use of sensitive patient data presents substantial privacy and confidentiality challenges.

Compliance with rules such as GDPR, HIPAA, and national data protection legislation challenging. Large-scale deployment of AI-driven systems is constrained by the dangers of data breaches and the exploitation of private health information.

3. Insufficient Standardization

When developing AI-based formulations, there is no common standard for data formats, model validation, or performance assessment. Variability in datasets and algorithms makes it difficult to compare outcomes across studies and inhibits reproducibility[18].

4. Interpretability and Transparency of the Model

A lot of AI models operate as "black boxes," especially deep learning algorithms. It is difficult to defend AI-driven choices in medication design and patient-specific dose forms when there is a lack of explainability, which erodes confidence among formulation scientists, physicians, and regulators.

5. Limited Applicability

AI models trained on certain populations or datasets may not perform effectively across varied patient groups. The wider application of patient-centered formulations may be limited by differences in age, gender, ethnicity, disease status, and lifestyle factors[19].

6. Barriers to Regulation and Validation

Regulatory bodies need clinical relevance, transparency, and strong validation. Approval pathways for AI-guided tailored formulations are questionable since current regulatory frameworks are not entirely geared to continually learning AI systems

7. High Cost and Infrastructure Requirements

AI system implementation requires sophisticated computer infrastructure, trained staff, and ongoing maintenance, all of which can be expensive. Small- and medium-scale pharmaceutical firms may suffer financial and technical obstacles[20].

8. Combining Current Formulation Techniques

It is difficult to integrate AI tools with conventional formulation development methods. Resistance to change, lack of AI literacy among formulation scientists, and dependency on conventional trial-and-error procedures hinder adoption.

9. Ethical Concerns and Bias

Biases in training data may be inadvertently included into AI models, resulting in unfair or less-than-ideal treatment outcomes for specific patient groups. Fairness, accountability, and informed consent are ethical issues that continue to be major constraints.

10. Limited Clinical Translation

Due to validation gaps and a lack of long-term clinical data, many patient-centered AI models fail to go from laboratory-scale development to real-world clinical application despite encouraging research results[21].

CONCLUSION:

A revolutionary discovery in the creation of pharmaceutical formulations is patient-centered artificial intelligence. Artificial intelligence (AI) is changing the paradigm from conventional population-based techniques to customized therapeutic treatments by incorporating patient-specific physiological, genetic, clinical, and behavioral data into formulation creation. By

facilitating predictive modeling, optimal excipient selection, customized dose forms, and controlled drug delivery systems that improve safety, efficacy, and adherence, this shift advances precision medicine[22].

Artificial intelligence (AI)-powered solutions like machine learning, deep learning, and hybrid modeling systems speed up formulation optimization, increase decision-making accuracy, and drastically lessen the need for empirical trial-and-error techniques. Additionally, better therapeutic results, fewer side effects, higher quality of life, and more economical healthcare delivery are all made possible by patient-centered AI. Formulation scientists can create medications that are both practically and scientifically acceptable to a wide range of patient populations thanks to its capacity to examine intricate, multidimensional datasets[23].

Notwithstanding its encouraging promise, a number of obstacles still need to be overcome, such as restrictions on data quality, privacy issues, legislative ambiguities, model interpretability problems, infrastructure requirements, and moral considerations like prejudice and responsibility. Successful implementation will depend on overcoming these challenges through interdisciplinary cooperation, transparent algorithms, strong clinical validation, uniform regulatory frameworks, and responsible data governance[24].

In the end, patient-centered AI has the potential to revolutionize the development of pharmaceutical formulations by coordinating scientific advancement with the specific requirements of each patient. AI-driven formulation techniques are set to become a key component of future pharmaceutical research and customized treatment design as computational technologies advance and healthcare systems adopt precision medicine more and more.[25]

REFERENCES

1. Chaudhary, P., et al. (2018). Bioactivities of phytochemicals present in tomato. Journal of Food Science and Technology. DOI: 10.1007/s13197-018-3221-z
2. Takeda, S., et al. (2021). Lycoperoside H, a Tomato Seed Saponin, Improves Epidermal Dehydration by Increasing Ceramide in the Stratum Corneum and Steroidal Anti-Inflammatory Effect. Molecules. DOI: 10.3390/molecules26195860
3. Izumi, T., et al. (2021). Tomato Seed Extract Containing Lycoperoside H Improves Skin Elasticity. Journal of Cosmetics, Dermatological Sciences and Applications. DOI: 10.4236/jcdsa.2021.113019
4. Li, J., et al. (2021). Chemical Composition of Tomato Seed Flours, and Their Radical Scavenging, Anti-Inflammatory and Gut Microbiota Modulating Properties. Molecules. DOI: 10.3390/molecules26061649
5. Yang, M., et al. (2024). Tomato-derived nanovesicles accelerate diabetic wound healing by modulating macrophage polarization and enhancing angiogenesis. DOI: Chen, H., et al. (2022).
6. Development of a tomato seed oil-loaded emulgel for chronic wound management: Formulation and in vivo evaluation. DOI: 10.1016/j.ijbiomac.2022.01.08810.1016/j.jconrel.2023.12.015
7. Zhu, Y., et al. (2023). Engineering of Bioactive Scaffolds for Chronic Wound Healing. DOI: 10.1016/j.bioactmat.2022.05.021

8. Honda, M., et al. (2019). Stabilization of Carotenoids by Encapsulation. DOI: 10.3390/molecules24142643
9. Crossen, S. L., et al. (2024). Comparative Analysis of Zero-Order and Higuchi Permeation Kinetics in Topical Cargo Systems. DOI: 10.1016/j.jconrel.2023.12.015
10. Kaoui, M., et al. (2024). Mathematical Modeling of Drug Delivery from Bi-Layered Core-Shell Polymeric Microspheres. DOI: 10.1101/2024.01.11.575289
11. Lagraeca, E., et al. (2020). Recent advances in the formulation of PLGA microparticles for controlled drug delivery. DOI: 10.3390/molecules25225244
12. Gref, R., et al. (2012). Surface-engineered nanoparticles for systemic drug delivery. Science. DOI: 10.1126/science.263.5153.1600
13. Yang, M., et al. (2024). Tomato-derived nanovesicles accelerate diabetic wound healing. Journal of Controlled Release. DOI: 10.1016/j.jconrel.2023.12.015
14. Chen, H., et al. (2022). Development of a tomato seed oil-loaded emulgel. International Journal of Biological Macromolecules. DOI: 10.1016/j.ijbiomac.2022.01.088
15. Chaudhary, P., et al. (2018). Bioactivities of phytochemicals present in tomato. DOI: 10.1007/s13197-018-3221-z
16. Umar, S., et al. (2022). Lycopene ameliorates diabetic complications by modulating Nrf2/HO-1 signaling. DOI: 10.1016/j.pharep.2022.04.011Li, J., et al. (2021). Chemical Composition of Tomato Seed Flours and Their Anti-Inflammatory Properties. DOI: 10.3390/molecules26061649
17. Umar, S., et al. (2022). Lycopene ameliorates diabetic complications by modulating signaling pathways. DOI: 10.1016/j.pharep.2022.04.011
18. Ghorpade, V. S., et al. (2019). Citric acid cross-linked carboxymethyl cellulose-polyvinyl alcohol hydrogel films for drug delivery. DOI: 10.1016/j.ijbiomac.2018.12.113
19. Zia, M. A., et al. (2021). Extraction and characterization of tomato seed oil for pharmaceutical potential. DOI: 10.1155/2021/6625841
20. Saeed, M., et al. (2023). Phytochemical screening and antimicrobial potential of tomato seed waste. DOI: 10.1002/fsn3.3451
21. Siddiqui, S. A., et al. (2025). Bioactive compounds from tomato processing by-products: Pharmaceutical applications. DOI: 10.1016/j.foodchem.2024.139021
22. Kaoui, M., et al. (2024). Mathematical Modeling of Drug Delivery from Bi-Layered Core-Shell Polymeric Microspheres. DOI: 10.1101/2024.01.11.575289
23. Honda, M., et al. (2019). Stabilization of Carotenoids by Encapsulation and Lipid-Based Delivery. DOI: 10.
24. Ibrahim, S. A., & Li, S. K. (2010). Chemical enhancers for transdermal drug delivery. DOI: 10.1517/17425241003612345 3390/molecules24142643
25. Umar, S., et al. (2022). Lycopene ameliorates diabetic complications by modulating signaling pathways. DOI: 10.1016/j.pharep.2022.04.011
26. Umar, S., et al. (2022). Lycopene ameliorates diabetic complications by modulating signaling pathways. DOI: 10.1016/j.pharep.2022.04.011
27. Milner, S. E., et al. (2011). Bio-activities of glycoalkaloids and their aglycones from Solanum species. DOI: 10.1016/j.phytochem.2011.03.013
28. Li, J., et al. (2021). Chemical Composition of Tomato Seed Flours and Their Anti-

Inflammatory Properties. DOI: 10.3390/molecules26061649
29. Kadler, K. E., et al. (2008). Collagen fibrillogenesis: fibronectin, integrins, and collagens VI and XI. DOI: 10.1016/j.ceb.2008.05.008 (Fundamental ref for the mechanism).
30. Belingheri, L., et al. (2024). Characterization of bioactive compounds from tomato seeds for dermo-cosmetic applications. DOI: 10.1016/j.foodchem.2023.138000
31. Belingheri, L., et al. (2024). Characterization of bioactive compounds from tomato seeds for dermo-cosmetic and pharmaceutical applications: A safety assessment. DOI: 10.1016/j.foodchem.2023.138000
32. Chen, H., et al. (2022). Development of a tomato seed oil-loaded emulgel: Safety, irritation potential, and in vivo evaluation. DOI: 10.1016/j.ijbiomac.2022.01.088
33. Dash, M., et al. (2020). Decellularized extracellular matrix and polysaccharide-based hybrid scaffolds: A biocompatibility review. DOI: 10.3390/molecules25112642
34. Saeed, M., et al. (2023). Phytochemical screening and antidiabetic potential of tomato seed waste: An in silico and in vitro approach. DOI: 10.1002/fsn3.3451
35. Silva-Beltrán, N. P., et al. (2021). Characterization of tomato by-products: A metabolomic approach to pharmaceutical potential. DOI: 10.1111/jfbc.13813
36. Bhoon, S., et al. (2023). Gas chromatography-mass spectrometry (GC-MS) analysis of seed oils for transdermal systems. DOI: 10.1016/j.chroma.2023.463982
37. Ahammad, F., et al. (2021). Identification of novel anti-diabetic agents from tomato seeds: A molecular docking and dynamics study. DOI: 10.1016/j.compbiolchem.2021.107534
38. Morris, G. M., et al. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. DOI: 10.1002/jcc.21256
39. Mezzomo, N., et al. (2023). Kinetic stability and degradation of carotenoids in lipid-based drug delivery systems. DOI: 10.1016/j.foodres.2022.112000
40. Honda, M., et al. (2022). Photostability of Lycopene in Bio-polymeric Microparticles under Accelerated Light Stress. DOI: 10.1016/j.lwt.2021.112832
41. Lagraeca, E., et al. (2020). Shelf-Life Prediction and Stability of Carotenoid-Loaded Polymeric Micro-Carriers. DOI: 10.3390/molecules25225244
42. Belingheri, L., et al. (2024). Characterization of bioactive compounds from tomato seeds for pharmaceutical applications: The entourage effect. DOI: 10.1016/j.foodchem.2023.138000
43. Boon, C. S., et al. (2010). Factors influencing the chemical stability of carotenoids in pharmaceutical systems. DOI: 10.1080/10408390802565889
44. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. DOI: 10.1111/j.1476-5381.2011.01238.x
45. Silva-Beltrán, N. P., et al. (2021). Characterization of tomato by-products: A metabolomic approach to pharmaceutical potential. DOI: 10.1111/jfbc.13813

HOW TO CITE: Khan Mohd Aftab Nisar, Sejal Sunil D'silva, Bioengineered Lycopene Micro-Scaffolds for Diabetic Wound Regeneration, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 1834-1842. https://doi.org/10.5281/zenodo.20086013